newsfilter
← Latest News
GlobeNewswire·

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH)